

Chen Haiquan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1363273/publications.pdf>

Version: 2024-02-01

223
papers

7,832
citations

57631

44
h-index

71532

76
g-index

228
all docs

228
docs citations

228
times ranked

9789
citing authors

#	ARTICLE	IF	CITATIONS
1	The prognostic value of Kirsten rat sarcoma viral oncogene homolog mutations in resected lung adenocarcinoma differs according to clinical features. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 163, e73-e85.	0.4	18
2	Surgery for pre- and minimally invasive lung adenocarcinoma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 163, 456-464.	0.4	33
3	Commentary: Is sublobar resection enough for ground-glass opacity“dominant lung adenocarcinoma?. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 163, 303-304.	0.4	3
4	Commentary: The ground-glass opacity: “The savior” for lung cancer?. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 163, 803-804.	0.4	0
5	Surgical Strategies for Pre- and Minimally Invasive Lung Adenocarcinoma 3.0: Lessons Learned From the Optimal Timing of Surgical Intervention. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2022, 34, 311-314.	0.4	11
6	Subsolid Lesions Exceeding 3 Centimeters: The Ground-Glass Opacity Component Still Matters. <i>Annals of Thoracic Surgery</i> , 2022, 113, 984-992.	0.7	5
7	Subsolid Lung Adenocarcinomas: Radiological, Clinical and Pathological Features and Outcomes. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2022, 34, 702-710.	0.4	11
8	Decreasing Prevalence of Benign Etiology in Resected Lung Nodules Suspicious for Lung Cancer over the Last Decade. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2022, 34, 1093-1099.	0.4	6
9	Clinical, pathological and radiologic features of minute pulmonary meningotheial-like nodules. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1473-1479.	1.2	2
10	Overuse of follow-up chest computed tomography in patients with incidentally identified nodules suspicious for lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1147-1152.	1.2	1
11	PD-L1 Expression and Comprehensive Molecular Profiling Predict Survival in Nonsmall Cell Lung Cancer: A Real-World Study of a Large Chinese Cohort. <i>Clinical Lung Cancer</i> , 2022, 23, 43-51.	1.1	11
12	NRAS expression is associated with prognosis and tumor immune microenvironment in lung adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 565-575.	1.2	4
13	Prognostic implication of tumor spread through air spaces in patients with pathologic NO lung adenocarcinoma. <i>Lung Cancer</i> , 2022, 164, 33-38.	0.9	11
14	Emerging High-Risk Population of Lung Cancer: To Reveal the Unrevealed. <i>Journal of Thoracic Oncology</i> , 2022, 17, e18-e20.	0.5	1
15	Loss of <i>TSC1/TSC2</i> sensitizes immune checkpoint blockade in non“small cell lung cancer. <i>Science Advances</i> , 2022, 8, eabi9533.	4.7	16
16	The Grading System of Lung Adenocarcinoma: Ever-Evolving Concepts. <i>Journal of Thoracic Oncology</i> , 2022, 17, e30.	0.5	0
17	Association of the programmed death ligand“1 combined positive score in tumors and clinicopathological features in esophageal cancer. <i>Thoracic Cancer</i> , 2022, 13, 523-532.	0.8	8
18	Pregnancy may have little influence on ground-glass opacities suspected for lung adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, , 1.	1.2	0

#	ARTICLE	IF	CITATIONS
19	Detection and treatment of lung adenocarcinoma at pre-/minimally invasive stage: is it lead-time bias?. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2717-2722.	1.2	4
20	Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma. Journal of Thoracic and Cardiovascular Surgery, 2021, 162, 664-674.e7.	0.4	34
21	Computed tomography density is not associated with pathological tumor invasion for pure ground-glass nodules. Journal of Thoracic and Cardiovascular Surgery, 2021, 162, 451-459.e3.	0.4	21
22	Gefitinib as neoadjuvant therapy for resectable stage II-III non-small cell lung cancer: A phase II study. Journal of Thoracic and Cardiovascular Surgery, 2021, 161, 434-442.e2.	0.4	58
23	Evolutionary Action Score of TP53 Enhances the Prognostic Prediction for Stage I Lung Adenocarcinoma. Seminars in Thoracic and Cardiovascular Surgery, 2021, 33, 221-229.	0.4	2
24	Impact of postoperative serum albumin level on anastomotic leakage after transthoracic oesophagectomy for oesophageal squamous cell carcinoma. ANZ Journal of Surgery, 2021, 91, E7-E13.	0.3	6
25	Excellent Prognosis of Patients With Invasive Lung Adenocarcinomas During Surgery Misdiagnosed as Atypical Adenomatous Hyperplasia, Adenocarcinoma In Situ, or Minimally Invasive Adenocarcinoma by Frozen Section. Chest, 2021, 159, 1265-1272.	0.4	16
26	Is 99m Tc bone scintigraphy necessary in the preoperative workup for patients with cT1N0 subsolid lung cancer? A prospective multicenter cohort study. Thoracic Cancer, 2021, 12, 415-419.	0.8	2
27	Esophagectomy With Three-Field Versus Two-Field Lymphadenectomy for Middle and Lower Thoracic Esophageal Cancer: Long-Term Outcomes of a Randomized Clinical Trial. Journal of Thoracic Oncology, 2021, 16, 310-317.	0.5	56
28	Comparative Efficacy and Safety of PD-1/PD-L1 Inhibitors for Patients with Solid Tumors: A Systematic Review and Bayesian Network Meta-analysis. Journal of Cancer, 2021, 12, 1133-1143.	1.2	14
29	Clinical Characteristics and Outcomes of COVID-19-Infected Cancer Patients: A Systematic Review and Meta-Analysis. Journal of the National Cancer Institute, 2021, 113, 371-380.	3.0	153
30	Ground Glass Opacity-Predominant Lung Cancer Is Independently Associated With Node Negative Status. Annals of Thoracic Surgery, 2021, 111, 1406-1407.	0.7	0
31	Lung cancer screening strategy for non-high-risk individuals: a narrative review. Translational Lung Cancer Research, 2021, 10, 452-461.	1.3	8
32	<i>Nanog</i> maintains stemness of <i>Lkb1</i> -deficient lung adenocarcinoma and prevents gastric differentiation. EMBO Molecular Medicine, 2021, 13, e12627.	3.3	5
33	Response to Cottu, Bozec, Basse, and Paoletti. Journal of the National Cancer Institute, 2021, 113, 344-345.	3.0	0
34	Combination of CD47 and CD68 expression predicts survival in eastern-Asian patients with non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2021, 147, 739-747.	1.2	8
35	Dynamic Modeling and Analysis of the Telescopic Sleeve Antiswing Device for Shipboard Cranes. Mathematical Problems in Engineering, 2021, 2021, 1-15.	0.6	2
36	Chromobox 4 facilitates tumorigenesis of lung adenocarcinoma through the Wnt/ β 2-catenin pathway. Neoplasia, 2021, 23, 222-233.	2.3	15

#	ARTICLE	IF	CITATIONS
37	Is flexible bronchoscopy necessary in the preoperative workup of patients with peripheral cT1N0 subsolid lung cancer? â€”a prospective multi-center cohort study. Translational Lung Cancer Research, 2021, 10, 1635-1641.	1.3	2
38	Primary Tumor Resection Improves Survival for EGFR-TKI-Treated Patients With Occult M1a Lung Adenocarcinoma. Frontiers in Oncology, 2021, 11, 622723.	1.3	2
39	Ground glass opacity featured lung adenocarcinoma in teenagers. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3719-3724.	1.2	4
40	Unlocking Better Survival for Esophageal Cancer Patients: Is Thoracic Duct Resection the Key?. Annals of Surgical Oncology, 2021, 28, 4086-4087.	0.7	0
41	Updated overall survival (OS) and exploratory analysis from the randomized, phase II EVAN study of erlotinib (E) versus vinorelbine plus cisplatin (NP) as adjuvant therapy in Chinese patients with stage IIIA EGFR+ NSCLC.. Journal of Clinical Oncology, 2021, 39, 8520-8520.	0.8	6
42	Lung cancer screening: who pays? who receives?â€”the Chinese perspective. Translational Lung Cancer Research, 2021, 10, 2389-2394.	1.3	10
43	Risk stratification model for patients with stage I invasive lung adenocarcinoma based on clinical and pathological predictors. Translational Lung Cancer Research, 2021, 10, 2205-2217.	1.3	6
44	Timeâ€”varying effect of sex on prognosis of lung adenocarcinoma surgical patients in China. Thoracic Cancer, 2021, 12, 1699-1707.	0.8	4
45	Induction of APOBEC3 Exacerbates DNA Replication Stress and Chromosomal Instability in Early Breast and Lung Cancer Evolution. Cancer Discovery, 2021, 11, 2456-2473.	7.7	74
46	Genetic-pathological prediction for timing and site-specific recurrence pattern in resected lung adenocarcinoma. European Journal of Cardio-thoracic Surgery, 2021, 60, 1223-1231.	0.6	6
47	Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma. Journal of Thoracic Disease, 2021, 13, 3518-3528.	0.6	49
48	Systemic immune-inflammation index is a stage-dependent prognostic factor in patients with operable non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 3144-3154.	1.3	15
49	Commentary: Total lung sparing for low-grade bronchial malignancies: Technically feasible, but still needs long-term survival data. JTCVS Techniques, 2021, 8, 202.	0.2	0
50	DDX56 modulates post-transcriptional Wnt signaling through miRNAs and is associated with early recurrence in squamous cell lung carcinoma. Molecular Cancer, 2021, 20, 108.	7.9	18
51	Targeting<i>HER2</i> Exon 20 Insertionâ€”Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib. Cancer Research, 2021, 81, 5311-5324.	0.4	31
52	Impact of Adjuvant Therapy on Survival in Surgically Resected Limited-Stage Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 704517.	1.3	1
53	Clinicopathologic Features and Response to Therapy of<i>NRG1</i> Fusionâ€”Driven Lung Cancers: The eNRGy1 Global Multicenter Registry. Journal of Clinical Oncology, 2021, 39, 2791-2802.	0.8	32
54	Validation of the Novel International Association for the Study of Lung Cancer Grading System for Invasive Pulmonary Adenocarcinoma and Association With Common Driver Mutations. Journal of Thoracic Oncology, 2021, 16, 1684-1693.	0.5	54

#	ARTICLE	IF	CITATIONS
55	The Best Surgery Should Be Applied for Locally Advanced Esophageal Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 3189-3190.	0.8	5
56	Targeting HSPA1A in ARID2-deficient lung adenocarcinoma. <i>National Science Review</i> , 2021, 8, nwab014.	4.6	9
57	Commentary: Anatomical partial lobectomy: the indications should be better defined.. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, , .	0.4	0
58	Integrative analysis of multi-omics data reveals the heterogeneity and signatures of immune therapy for small cell lung cancer. <i>Clinical and Translational Medicine</i> , 2021, 11, e620.	1.7	6
59	Survival Prediction and Adjuvant Chemotherapy Based on Tumor Marker for Stage IB Lung Adenocarcinoma. <i>Annals of Thoracic Surgery</i> , 2020, 109, 927-937.	0.7	4
60	Does [18F] fluorodeoxyglucose-positron emission tomography/computed tomography have a role in cervical nodal staging for esophageal squamous cell carcinoma?. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 160, 544-550.	0.4	10
61	Segment Location and Ground Glass Opacity Ratio Reliably Predict Node-Negative Status in Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2020, 109, 1061-1068.	0.7	32
62	Marital status independently predicts non-small cell lung cancer survival: a propensity-adjusted SEER database analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 67-74.	1.2	61
63	Imaging Features Suggestive of Multiple Primary Lung Adenocarcinomas. <i>Annals of Surgical Oncology</i> , 2020, 27, 2061-2070.	0.7	22
64	Results of low-dose computed tomography as a regular health examination among Chinese hospital employees. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 160, 824-831.e4.	0.4	86
65	Commentary: Nonadherence to guidelines: It is important to investigate the reasons and survival outcomes. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 162, 662-663.	0.4	0
66	Integrated analysis of optical mapping and whole-genome sequencing reveals intratumoral genetic heterogeneity in metastatic lung squamous cell carcinoma. <i>Translational Lung Cancer Research</i> , 2020, 9, 670-681.	1.3	11
67	What is the appropriate surgical strategy for pulmonary metastasis of colorectal cancer?. <i>Medicine (United States)</i> , 2020, 99, e21368.	0.4	6
68	Commentary: How to evaluate the effect of neoadjuvant therapy for esophageal cancer? More studies are still needed. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 162, 1645-1646.	0.4	0
69	Uniportal versus multiportal video-assisted thoracoscopic anatomical resection for NSCLC: a meta-analysis. <i>Journal of Cardiothoracic Surgery</i> , 2020, 15, 238.	0.4	11
70	EGFR-mutant lung adenocarcinoma harboring co-mutational tumor suppressor genes predicts poor prognosis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1781-1789.	1.2	13
71	Management of Ground-Glass Opacities in the Lung Cancer Spectrum. <i>Annals of Thoracic Surgery</i> , 2020, 110, 1796-1804.	0.7	98
72	Development and validation of a five-gene model to predict postoperative brain metastasis in operable lung adenocarcinoma. <i>International Journal of Cancer</i> , 2020, 147, 584-592.	2.3	23

#	ARTICLE	IF	CITATIONS
73	Comparison of outcomes following segmentectomy or lobectomy for patients with clinical NO invasive lung adenocarcinoma of 2Åcm or less in diameter. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1603-1613.	1.2	12
74	Three-field <i>versus</i> two-field lymphadenectomy in transthoracic oesophagectomy for oesophageal squamous cell carcinoma: short-term outcomes of a randomized clinical trial. British Journal of Surgery, 2020, 107, 647-654.	0.1	25
75	Ground-glass opacity-featured lung adenocarcinoma has no response to chemotherapy. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2411-2417.	1.2	5
76	Commentary: Challenges to thoracic surgeons in the global coronavirus pandemic. Journal of Thoracic and Cardiovascular Surgery, 2020, 160, 593-594.	0.4	1
77	The lymph node status and histologic subtypes influenced the effect of postoperative radiotherapy on patients with N2 positive IIIA non-“small cell lung cancer. Journal of Surgical Oncology, 2019, 119, 379-387.	0.8	26
78	Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations. Lancet Respiratory Medicine, the, 2019, 7, 881-891.	5.2	167
79	Risk factors of chylothorax after esophagectomy. Journal of Thoracic Disease, 2019, 11, 1749-1752.	0.6	7
80	Distinct Prognostic Factors in Patients with Stage IANon-“Small Cell Lung Cancer with Radiologic Part-Solid or Solid Lesions. Journal of Thoracic Oncology, 2019, 14, 2133-2142.	0.5	120
81	Real World Experience of Crizotinib in 104 Patients With ALK Rearrangement Non-small-cell Lung Cancer in a Single Chinese Cancer Center. Frontiers in Oncology, 2019, 9, 1116.	1.3	18
82	Detection of Novel NRG1, EGFR, and MET Fusions in Lung Adenocarcinomas in the Chinese Population. Journal of Thoracic Oncology, 2019, 14, 2003-2008.	0.5	52
83	<p>>Chinese perspectives on clinical efficacy and safety of alectinib in patients with >ALK-positive advanced non-small cell lung cancer<p>>. OncoTargets and Therapy, 2019, Volume 12, 6481-6495.	1.0	4
84	Primary Gastrointestinal-Type Clear Cell Sarcoma-“like Tumor of the Bronchus: A Hitherto Unreported Bronchial Tumor. Journal of Thoracic Oncology, 2019, 14, e202-e205.	0.5	5
85	Comparative analysis of co-occurring mutations of specific tumor suppressor genes in lung adenocarcinoma between Asian and Caucasian populations. Journal of Cancer Research and Clinical Oncology, 2019, 145, 747-757.	1.2	8
86	A prognostic score system with lymph node ratio in stage IIIA-N2 NSCLC patients after surgery and adjuvant chemotherapy. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2115-2122.	1.2	9
87	Outcomes comparison between neoadjuvant chemotherapy and adjuvant chemotherapy in stage IIIA non-small cell lung cancer patients. Journal of Thoracic Disease, 2019, 11, 1443-1455.	0.6	9
88	Predicting the Value of Adjuvant Therapy in Esophageal Squamous Cell Carcinoma by Combining the Total Number of Examined Lymph Nodes with the Positive Lymph Node Ratio. Annals of Surgical Oncology, 2019, 26, 2367-2374.	0.7	21
89	A Pathologic Complete Response to Neoadjuvant Chemotherapy and Immunotherapy Followed by Surgery in a Patient With NSCLC. Journal of Thoracic Oncology, 2019, 14, e104-e106.	0.5	1
90	tRNA-“based prognostic score in predicting survival outcomes of lung adenocarcinomas. International Journal of Cancer, 2019, 145, 1982-1990.	2.3	18

#	ARTICLE	IF	CITATIONS
91	Crizotinib in Chinese Patients with ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer in Routine Clinical Practice. <i>Targeted Oncology</i> , 2019, 14, 315-323.	1.7	22
92	Lung cancer incidence in female rises significantly in urban sprawl of Shanghai after introduction of LDCT screening. <i>Lung Cancer</i> , 2019, 132, 114-118.	0.9	17
93	Integration of whole-genome sequencing and functional screening identifies a prognostic signature for lung metastasis in triple-negative breast cancer. <i>International Journal of Cancer</i> , 2019, 145, 2850-2860.	2.3	12
94	Lung cancer deficient in the tumor suppressor GATA4 is sensitive to TGFBR1 inhibition. <i>Nature Communications</i> , 2019, 10, 1665.	5.8	45
95	Esophageal squamous cell carcinoma patients with positive lymph nodes benefit from extended radical lymphadenectomy. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019, 157, 1275-1283.e1.	0.4	10
96	Lung Adenocarcinomas Manifesting as Radiological Part-Solid Nodules Define a Special Clinical Subtype. <i>Journal of Thoracic Oncology</i> , 2019, 14, 617-627.	0.5	151
97	Proteomic analysis of plasma exosomes to differentiate malignant from benign pulmonary nodules. <i>Clinical Proteomics</i> , 2019, 16, 5.	1.1	15
98	Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition). <i>Translational Lung Cancer Research</i> , 2019, 8, 1163-1173.	1.3	34
99	Genomic and immune profiling of pre-invasive lung adenocarcinoma. <i>Nature Communications</i> , 2019, 10, 5472.	5.8	127
100	International expert consensus on the management of bleeding during VATS lung surgery. <i>Annals of Translational Medicine</i> , 2019, 7, 712-712.	0.7	23
101	Correlation between PD-L1 expression and clinicopathological characteristics of non-small cell lung cancer: A real-world study of a large Chinese cohort. <i>Journal of Thoracic Disease</i> , 2019, 11, 4591-4601.	0.6	35
102	Frequency and clinical significance of <i>NF1</i> mutation in lung adenocarcinomas from East Asian patients. <i>International Journal of Cancer</i> , 2019, 144, 290-296.	2.3	13
103	Neoadjuvant or adjuvant chemotherapy for non-small-cell lung cancer: Does the timing matter?. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019, 157, 756-757.	0.4	4
104	Preoperative brain MRI for clinical stage IA lung cancer: is routine scanning rational?. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 503-509.	1.2	7
105	Direct comparison between video-assisted thoracoscopic surgery and muscle-sparing minithoracotomy in the era of minimally invasive thoracic surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, 1307-1308.	0.4	0
106	Tumor histology predicts mediastinal nodal status and may be used to guide limited lymphadenectomy in patients with clinical stage I non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, 2648-2656.e2.	0.4	31
107	In vivo CRISPR screening unveils histone demethylase UTX as an important epigenetic regulator in lung tumorigenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E3978-E3986.	3.3	78
108	Prediction of surgical outcomes of extended thymectomy for patients with myasthenia gravis: Where are we now?. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, 2745.	0.4	0

#	ARTICLE	IF	CITATIONS
109	A comprehensive evaluation of clinicopathologic characteristics, molecular features and prognosis in lung adenocarcinoma with solid component. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 725-734.	1.2	17
110	Prognostic value of EGFR family expression in lymph node-negative esophageal squamous cell carcinoma patients. <i>Pathology Research and Practice</i> , 2018, 214, 1017-1023.	1.0	4
111	Surgery is crucial for advanced esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, 2722-2723.	0.4	1
112	Predictors of recurrence and survival of pathological T1N0M0 invasive adenocarcinoma following lobectomy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1015-1023.	1.2	19
113	Are exon 19 deletions and L858R different in early stage lung adenocarcinoma?. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 165-171.	1.2	6
114	Does delayed esophagectomy after endoscopic resection affect outcomes in patients with stage T1 esophageal cancer? A propensity score-based analysis. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2018, 32, 1441-1448.	1.3	14
115	Impact of Solid Minor Histologic Subtype in Postsurgical Prognosis of Stage I Lung Adenocarcinoma. <i>Annals of Thoracic Surgery</i> , 2018, 105, 302-308.	0.7	18
116	Upfront surgery as first-line therapy in selected patients with stage IIIA non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, 1814-1822.e4.	0.4	30
117	Commentary on the impacts of postoperative complications on survival after lung cancer surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, 1265-1266.	0.4	3
118	Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials. <i>Oncolmmunology</i> , 2018, 7, e1396403.	2.1	60
119	The Society for Translational Medicine: indications and methods of percutaneous transthoracic needle biopsy for diagnosis of lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 5538-5544.	0.6	17
120	Chinese expert consensus on mediastinal lymph node dissection in esophagectomy for esophageal cancer (2017 edition). <i>Journal of Thoracic Disease</i> , 2018, 10, 2481-2489.	0.6	37
121	Selective versus systematic lymph node dissection (other than sampling) for clinical N2-negative non-small cell lung cancer: a meta-analysis of observational studies. <i>Journal of Thoracic Disease</i> , 2018, 10, 3428-3435.	0.6	14
122	Lung cancer screening in China: early-stage lung cancer and minimally invasive surgery 3.0. <i>Journal of Thoracic Disease</i> , 2018, 10, S1677-S1679.	0.6	10
123	Three-field versus two-field lymph node dissection for thoracic esophageal squamous cell carcinoma: a propensity score-matched comparison. <i>Journal of Thoracic Disease</i> , 2018, 10, 2924-2932.	0.6	16
124	Society for Translational Medicine Expert Consensus on the prevention and treatment of postoperative pulmonary infection in esophageal cancer patients. <i>Journal of Thoracic Disease</i> , 2018, 10, 1050-1057.	0.6	8
125	Adjuvant targeted therapy for resected NSCLC: to be or not to be?. <i>Journal of Thoracic Disease</i> , 2018, 10, S3297-S3299.	0.6	1
126	Upfront surgery is essential in selected patients with stage IIIA non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, E815-E816.	0.6	0

#	ARTICLE	IF	CITATIONS
127	Society for Translational Medicine Expert Consensus on the preoperative assessment of circulatory and cardiac functions and criteria for the assessment of risk factors in patients with lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 5545-5549.	0.6	8
128	Society for Translational Medicine expert consensus on training and certification standards for surgeons and assistants in minimally invasive surgery for lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 5666-5672.	0.6	5
129	Esophageal cancer in elderly patients: a population-based study. <i>Journal of Thoracic Disease</i> , 2018, 10, 448-457.	0.6	18
130	Predictors of Pathologic Tumor Invasion and Prognosis for Ground Glass Opacity Featured Lung Adenocarcinoma. <i>Annals of Thoracic Surgery</i> , 2018, 106, 1682-1690.	0.7	50
131	ALK-rearrangement neuroendocrine carcinoma of the lung: a comprehensive study of a rare case series and review of literature. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 4991-4998.	1.0	31
132	A B7&CD28 family based signature demonstrates significantly different prognoses and tumor immune landscapes in lung adenocarcinoma. <i>International Journal of Cancer</i> , 2018, 143, 2592-2601.	2.3	21
133	The Society for Translational Medicine: the assessment and prevention of venous thromboembolism after lung cancer surgery. <i>Journal of Thoracic Disease</i> , 2018, 10, 3039-3053.	0.6	18
134	Society for Translational Medicine expert consensus on the use of antibacterial drugs in thoracic surgery. <i>Journal of Thoracic Disease</i> , 2018, 10, 6356-6374.	0.6	4
135	A model based on endoscopic morphology of submucosal esophageal squamous cell carcinoma for determining risk of metastasis on lymph nodes. <i>Journal of Thoracic Disease</i> , 2018, 10, 6846-6853.	0.6	9
136	Development and Validation of Web-Based&Nominograms to Precisely Predict&Conditional Risk of Site-Specific Recurrence for Patients With Completely Resected Non-small Cell Lung Cancer. <i>Chest</i> , 2018, 154, 501-511.	0.4	37
137	Thymoma and thymic carcinoma associated with multilocular thymic cyst: a clinicopathologic analysis of 18 cases. <i>Diagnostic Pathology</i> , 2018, 13, 41.	0.9	18
138	Clinical Significance of Complex Glandular Patterns in Lung Adenocarcinoma. <i>American Journal of Clinical Pathology</i> , 2018, 150, 65-73.	0.4	31
139	Extended Right Thoracic Approach Compared With Limited Left Thoracic Approach for Patients With Middle and Lower Esophageal Squamous Cell Carcinoma. <i>Annals of Surgery</i> , 2018, 267, 826-832.	2.1	49
140	Predicting prognosis of post-chemotherapy patients with resected IIIA non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 4186-4194.	0.6	5
141	Clinicopathologic Characteristics of Patients with HER2 Insertions in Non-small Cell Lung Cancer. <i>Annals of Surgical Oncology</i> , 2017, 24, 291-297.	0.7	22
142	The prognostic value of lymph node ratio and log odds of positive lymph nodes in patients with lung adenocarcinoma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2017, 153, 702-709.e1.	0.4	33
143	Ciliated muconodular papillary tumor of the lung harboring <i>ALK</i> gene rearrangement: Case report and review of the literature. <i>Pathology International</i> , 2017, 67, 171-175.	0.6	50
144	Predicting the recurrence risk factors and clinical outcomes of peripheral pulmonary adenocarcinoma&€%&3Ac with wedge resection. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1043-1051.	1.2	10

#	ARTICLE	IF	CITATIONS
145	Development of a novel prognostic signature of long non-coding RNAs in lung adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1649-1657.	1.2	30
146	Should Nonsmokers Be Excluded from Early Lung Cancer Screening with Low-Dose Spiral Computed Tomography? Community-Based Practice in Shanghai. <i>Translational Oncology</i> , 2017, 10, 485-490.	1.7	37
147	Comparison of outcomes between muscle-sparing thoracotomy and video-assisted thoracic surgery in patients with cT1 NO M0 lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2017, 154, 1420-1429.e1.	0.4	13
148	Comparison of particle beam therapy and stereotactic body radiotherapy for early stage non-small cell lung cancer: A systematic review and hypothesis-generating meta-analysis. <i>Radiotherapy and Oncology</i> , 2017, 123, 346-354.	0.3	62
149	The indication of completion lobectomy for lung adenocarcinoma after wedge resection during surgical operation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 2095-2104.	1.2	12
150	Surgical Outcomes of Isolated Malignant Pulmonary Nodules in Patients with a History of Breast Cancer. <i>Annals of Surgical Oncology</i> , 2017, 24, 3748-3753.	0.7	11
151	YAP Suppresses Lung Squamous Cell Carcinoma Progression via Deregulation of the DNp63-GPX2 Axis and ROS Accumulation. <i>Cancer Research</i> , 2017, 77, 5769-5781.	0.4	70
152	Comparative genomic analysis of esophageal squamous cell carcinoma between Asian and Caucasian patient populations. <i>Nature Communications</i> , 2017, 8, 1533.	5.8	92
153	Comprehensive investigation of clinicopathologic features, oncogenic driver mutations and immunohistochemical markers in peripheral lung squamous cell carcinoma. <i>Journal of Thoracic Disease</i> , 2017, 9, 4434-4440.	0.6	9
154	The non-small cell lung cancer EGFR extracellular domain mutation, M277E, is oncogenic and drug-sensitive. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4507-4515.	1.0	13
155	A nomogram based on phosphorylated AKT1 for predicting locoregional recurrence in patients with oesophageal squamous cell carcinoma. <i>Journal of Cancer</i> , 2017, 8, 3755-3763.	1.2	3
156	Results of neoadjuvant therapy followed by esophagectomy for patients with locally advanced thoracic esophageal squamous cell carcinoma. <i>Journal of Thoracic Disease</i> , 2017, 9, 318-326.	0.6	4
157	Selective lymph node dissection in early-stage non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, 2102-2107.	0.6	29
158	Unique distribution of programmed death ligand 1 (PD-L1) expression in East Asian non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, 2579-2586.	0.6	51
159	A novel BMX variant promotes tumor cell growth and migration in lung adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 33405-33415.	0.8	5
160	Super enhancer associated <i>RAI14</i> is a new potential biomarker in lung adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 105251-105261.	0.8	15
161	Three-field versus two-field lymphadenectomy for carcinoma of the middle and lower esophagus: Short-term results of a randomized controlled trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 4036-4036.	0.8	0
162	Effect of tumor size on prognosis of node-negative lung cancer with sufficient lymph node examination and no disease extension. <i>OncoTargets and Therapy</i> , 2016, 9, 649.	1.0	15

#	ARTICLE	IF	CITATIONS
163	The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations. <i>OncoTargets and Therapy</i> , 2016, 9, 833.	1.0	38
164	Robotic-assisted sleeve lobectomy for right upper lobe combining with middle lobe resection of lung cancer. <i>Journal of Visualized Surgery</i> , 2016, 2, 178-178.	0.2	7
165	Clinical and genetic features of lung squamous cell cancer in never-smokers. <i>Oncotarget</i> , 2016, 7, 35979-35988.	0.8	22
166	Identification of TRA2B-DNAH5 fusion as a novel oncogenic driver in human lung squamous cell carcinoma. <i>Cell Research</i> , 2016, 26, 1149-1164.	5.7	26
167	Former smokers with non-small-cell lung cancers: a comprehensive investigation of clinicopathologic characteristics, oncogenic drivers, and prognosis. <i>Cancer Medicine</i> , 2016, 5, 2117-2125.	1.3	8
168	The Histologic Classifications of Lung Adenocarcinomas Are Discriminable by Unique Lineage Backgrounds. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2161-2172.	0.5	7
169	Factors Affecting Hospital Mortality in Patients with Esophagogastric Anastomotic Leak: A Retrospective Study. <i>World Journal of Surgery</i> , 2016, 40, 1152-1157.	0.8	13
170	Minor Components of Micropapillary and Solid Subtypes in Lung Adenocarcinoma are Predictors of Lymph Node Metastasis and Poor Prognosis. <i>Annals of Surgical Oncology</i> , 2016, 23, 2099-2105.	0.7	108
171	Efficacy of EGFR Tyrosine Kinase Inhibitors in the Adjuvant Treatment for Operable Non-small Cell Lung Cancer by a Meta-Analysis. <i>Chest</i> , 2016, 149, 1384-1392.	0.4	48
172	Prevalence and clinicopathological characteristics of ALK fusion subtypes in lung adenocarcinomas from Chinese populations. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 833-843.	1.2	15
173	Precise Diagnosis of Intraoperative Frozen Section Is an Effective Method to Guide Resection Strategy for Peripheral Small-Sized Lung Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 307-313.	0.8	173
174	A propensity score matching analysis of survival following segmentectomy or wedge resection in early-stage lung invasive adenocarcinoma or squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 13880-13885.	0.8	9
175	Survival following segmentectomy or lobectomy in elderly patients with early-stage lung cancer. <i>Oncotarget</i> , 2016, 7, 19081-19086.	0.8	24
176	Neoadjuvant gefitinib for stage II-IIIa NSCLC with activating EGFR mutation (NCT01833572): an open-label, single-arm, phase II study. <i>Journal of Clinical Oncology</i> , 2016, 34, e20026-e20026.	0.8	0
177	A novel homebrew real-time PCR assay to detect ALK rearrangements in lung cancers and lymphomas. <i>Journal of Clinical Oncology</i> , 2016, 34, e23270-e23270.	0.8	0
178	Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1444-1450.	0.5	56
179	Incidence and management of chylothorax after esophagectomy. <i>Thoracic Cancer</i> , 2015, 6, 354-358.	0.8	67
180	Whole Exome Sequencing Identifies Frequent Somatic Mutations in Cell-Cell Adhesion Genes in Chinese Patients with Lung Squamous Cell Carcinoma. <i>Scientific Reports</i> , 2015, 5, 14237.	1.6	51

#	ARTICLE	IF	CITATIONS
181	EGFR Exon 18 Mutations in East Asian Patients with Lung Adenocarcinomas: A Comprehensive Investigation of Prevalence, Clinicopathologic Characteristics and Prognosis. <i>Scientific Reports</i> , 2015, 5, 13959.	1.6	34
182	Phosphorylated AKT1 is associated with poor prognosis in esophageal squamous cell carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 95.	3.5	19
183	When Should 99mTc Bone Scintigraphy Be Performed in cT1N0 Non-Small Cell Lung Cancer Patients?. <i>Medicine (United States)</i> , 2015, 94, e2309.	0.4	10
184	High-dose nimotuzumab improves the survival rate of esophageal cancer patients who underwent radiotherapy. <i>OncoTargets and Therapy</i> , 2015, 9, 117.	1.0	10
185	SOX2 expression is associated with FGFR fusion genes and predicts favorable outcome in lung squamous cell carcinomas. <i>OncoTargets and Therapy</i> , 2015, 8, 3009.	1.0	9
186	HGF and NRG1 protein expression are not poor prognostic markers in surgically resected lung adenocarcinoma. <i>OncoTargets and Therapy</i> , 2015, 8, 1185.	1.0	10
187	Prognostic value of Bcl-2 expression in patients with non-small-cell lung cancer: a meta-analysis and systemic review. <i>OncoTargets and Therapy</i> , 2015, 8, 3361.	1.0	22
188	Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients. <i>Oncotarget</i> , 2015, 6, 34300-34308.	0.8	70
189	Lung adenocarcinoma: Are skip N2 metastases different from non-skip?. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2015, 150, 790-795.	0.4	38
190	Is bronchoscopy necessary in the preoperative workup of a solitary pulmonary nodule?. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2015, 150, 36-40.	0.4	17
191	Comparison of Ivor-Lewis vs Sweet Esophagectomy for Esophageal Squamous Cell Carcinoma. <i>JAMA Surgery</i> , 2015, 150, 292.	2.2	73
192	LKB1 Inactivation Elicits a Redox Imbalance to Modulate Non-small Cell Lung Cancer Plasticity and Therapeutic Response. <i>Cancer Cell</i> , 2015, 27, 698-711.	7.7	118
193	Prevalence and Clinicopathological Characteristics of BRAF Mutations in Chinese Patients with Lung Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 1284-1291.	0.7	7
194	Comparison of clinicopathologic features and survival between eastern and western population with esophageal squamous cell carcinoma. <i>Journal of Thoracic Disease</i> , 2015, 7, 1780-6.	0.6	24
195	Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. <i>OncoTargets and Therapy</i> , 2014, 7, 567.	1.0	206
196	Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives. <i>OncoTargets and Therapy</i> , 2014, 7, 1689.	1.0	65
197	PIK3CA Mutations Frequently Coexist with EGFR/KRAS Mutations in Non-Small Cell Lung Cancer and Suggest Poor Prognosis in EGFR/KRAS Wildtype Subgroup. <i>PLoS ONE</i> , 2014, 9, e88291.	1.1	126
198	Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients. <i>OncoTargets and Therapy</i> , 2014, 7, 513.	1.0	32

#	ARTICLE	IF	CITATIONS
199	Comparison of clinical features, molecular alterations, and prognosis in morphological subgroups of lung invasive mucinous adenocarcinoma. <i>OncoTargets and Therapy</i> , 2014, 7, 2127.	1.0	18
200	Oncogenic mutations are associated with histological subtypes but do not have an independent prognostic value in lung adenocarcinoma. <i>OncoTargets and Therapy</i> , 2014, 7, 1423.	1.0	41
201	Reply. <i>Annals of Thoracic Surgery</i> , 2014, 98, 390.	0.7	0
202	Transdifferentiation of lung adenocarcinoma in mice with <i>Lkb1</i> deficiency to squamous cell carcinoma. <i>Nature Communications</i> , 2014, 5, 3261.	5.8	137
203	Recurrent TERT promoter mutations in non-small cell lung cancers. <i>Lung Cancer</i> , 2014, 86, 369-373.	0.9	27
204	A Comprehensive Investigation of Molecular Features and Prognosis of Lung Adenocarcinoma with Micropapillary Component. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1772-1778.	0.5	69
205	VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex. <i>Cell Research</i> , 2014, 24, 331-343.	5.7	238
206	YAP inhibits squamous transdifferentiation of <i>Lkb1</i> -deficient lung adenocarcinoma through ZEB2-dependent DNp63 repression. <i>Nature Communications</i> , 2014, 5, 4629.	5.8	95
207	A clinicopathologic prediction model for postoperative recurrence in stage Ia non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2014, 148, 1193-1199.	0.4	64
208	ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: A comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features. <i>Lung Cancer</i> , 2014, 84, 121-126.	0.9	194
209	FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non-small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 4107-4114.	3.2	125
210	Comprehensive Analysis of Oncogenic Mutations in Lung Squamous Cell Carcinoma With Minor Glandular Component. <i>Chest</i> , 2014, 145, 473-479.	0.4	36
211	The prognostic and predictive value of solid subtype in invasive lung adenocarcinoma. <i>Scientific Reports</i> , 2014, 4, 7163.	1.6	42
212	Analysis of the molecular and clinicopathologic features of surgically resected lung adenocarcinoma in patients under 40 years old. <i>Journal of Thoracic Disease</i> , 2014, 6, 1396-402.	0.6	27
213	Extent of lymph node dissection: common hepatic artery lymph node dissection can be omitted for esophageal squamous cell carcinoma. <i>Journal of Thoracic Disease</i> , 2014, 6 Suppl 3, S325-32.	0.6	4
214	Detecting somatic point mutations in cancer genome sequencing data: a comparison of mutation callers. <i>Genome Medicine</i> , 2013, 5, 91.	3.6	146
215	Sequential treatment of tyrosine kinase inhibitors and chemotherapy for EGFR-mutated non-small cell lung cancer: a meta-analysis of Phase III trials. <i>OncoTargets and Therapy</i> , 2013, 6, 1771.	1.0	7
216	RET Fusions Define a Unique Molecular and Clinicopathologic Subtype of Non-small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 4352-4359.	0.8	483

#	ARTICLE	IF	CITATIONS
217	Frequency of Driver Mutations in Lung Adenocarcinoma from Female Never-Smokers Varies with Histologic Subtypes and Age at Diagnosis. <i>Clinical Cancer Research</i> , 2012, 18, 1947-1953.	3.2	161
218	Pattern of lymphatic spread in thoracic esophageal squamous cell carcinoma: A single-institution experience. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2012, 144, 778-786.	0.4	52
219	Video-assisted thoracoscopic solitary pulmonary nodule resection after CT-guided hookwire localization: 43 cases report and literature review. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2011, 25, 1723-1729.	1.3	132
220	Spectrum of Oncogenic Driver Mutations in Lung Adenocarcinomas from East Asian Never Smokers. <i>PLoS ONE</i> , 2011, 6, e28204.	1.1	195
221	Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases. <i>Journal of Clinical Oncology</i> , 2010, 28, 4616-4620.	0.8	313
222	Anterior Versus Posterior Routes of Reconstruction After Esophagectomy: A Comparative Anatomic Study. <i>Annals of Thoracic Surgery</i> , 2009, 87, 400-404.	0.7	38
223	MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer. <i>Oncotarget</i> , 0, 7, 41691-41702.	0.8	68